M&A Deal Summary |
|
|---|---|
| Date | 2019-04-22 |
| Target | Eli Lilly - Antibiotics Brands & Manufacturing Facility |
| Sector | Medical Products |
| Buyer(s) | Eddingpharm |
| Sellers(s) | Lilly |
| Deal Type | Divestiture |
| Deal Value | 375M USD |
SEARCH BY
Try For Free 7-Day Free Trial
Eddingpharm is a fast-growing specialty pharmaceutical company, committed to bringing to the Chinese healthcare market high-quality medicines from all over the world, providing patients with more treatment options and better opportunities for recovery. Eddingpharm promotes the communication and collaboration between Chinese clinical experts and leading international medical research institutes, and provide academic support to Chinese clinical doctors.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector (Medical Products) | 1 of 1 |
| Type (Divestiture) | 1 of 1 |
| State (Indiana) | 1 of 1 |
| Country (United States) | 1 of 1 |
| Year (2019) | 1 of 1 |
| Size (of disclosed) | 1 of 1 |
| Category | Company |
|---|---|
| Founded | 1876 |
| Sector | Life Science |
| Employees | 43,000 |
| Revenue | 34.1B USD (2023) |
Lilly discovers, develops, manufactures, and markets products in two business segments—human pharmaceutical products and animal health products. The mission of its human pharmaceutical business is to make medicines that help people live longer, healthier, more active lives. Most of the products Eli Lilly sells were discovered or developed by its own scientists, and the Company's success depends to a great extent on its ability to continue to discover, develop, and bring to market innovative new medicines. Eli Lilly's animal health business, operating through its Elanco division, develops, manufactures, and markets products for both food animals and companion animals. Eli Lilly manufactures and distributes its products through facilities in the US, Puerto Rico, and 11 other countries. Lilly was founded in 1876 and is based in Indianapolis, Indiana.
| DEAL STATS | # |
|---|---|
| Overall | 9 of 9 |
| Sector (Medical Products) | 2 of 2 |
| Type (Divestiture) | 8 of 8 |
| State (Indiana) | 5 of 5 |
| Country (United States) | 9 of 9 |
| Year (2019) | 1 of 1 |
| Size (of disclosed) | 3 of 5 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2019-01-07 |
Loxo Oncology
Stamford, Connecticut, United States Loxo Oncology, Inc. is a biopharmaceutical company focused on the development and commercialization of highly selective medicines for patients with genomically defined cancers. Loxo Oncology, Inc. was founded in 2013 and is based in Stamford, Connecticut. |
Buy | $8.0B |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2020-01-01 |
Protomer Technologies
Pasadena, California, United States Protomer Technologies is engineering next-generation protein therapeutics that can sense molecular activators in the body to automatically activate as needed. Protomer Technologies develop therapeutic proteins that can sense small molecule activators to achieve variable dosing and targeted delivery. Protomer's chemical biology-based MEPS platform enables rapid turn-on and turn-off capability for automatic activity control of peptides and proteins and enables the development of targeted therapies with dual-homing to reduce off-target effects. Protomer Technologies was founded in 2015 and is based in Pasadena, California. |
Buy | - |
